What Triptorelin is
Triptorelin is a GnRH agonist peptide analog used in approved endocrine contexts requiring pituitary-gonadal suppression.
Triptorelin is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it is a serious peptide medicine and a useful contrast to casual hormone-optimization discourse online.
The useful starting point is to separate the molecule itself from the internet story around it. It is a serious peptide medicine and a useful contrast to casual hormone-optimization discourse online.
Why people keep looking it up
It is a serious peptide medicine and a useful contrast to casual hormone-optimization discourse online.
Triptorelin is a GnRH agonist peptide analog used in approved endocrine contexts requiring pituitary-gonadal suppression.
Triptorelin tends to stay in the conversation because it touches a familiar public theme: gnrh agonist, hormone suppression, and pituitary signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved endocrine peptide analog with direct human evidence.
Human trials and official labeling support specific approved uses.
Mechanism follows GnRH receptor pharmacology and downstream endocrine suppression.
Why this page carries the current tier: Approved endocrine peptide analog with direct human evidence.
The current seed trail for Triptorelin is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a consequential endocrine drug class, not a casual performance-peptide category.
FDA-approved triptorelin products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Triptorelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Triptorelin is CID 25074470. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 25074470
- Formula
- C64H82N18O13
- Molecular weight
- 1311.4
- InChIKey
- VXKHXGOKWPXYNA-PGBVPBMZSA-N
Matched synonyms include TRIPTORELIN, 57773-63-4, Triptoreline, Triptorelina, Arvekap, Triptorelinum, Triptodur, (D-Trp6)-GnRH.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Triptorelin returns 286 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Triptorelin returns 2449 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Trelstar
- Generic names
- TRIPTORELIN PAMOATE
- Routes
- Not linked
- Application numbers
- NDA020715, NDA021288, NDA022437
Indications and usage. 1 INDICATIONS AND USAGE TRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. TRELSTAR is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Hypersensitivity: Anaphylactic shock, hypersensitivity, and angioedema have been reported. In the event of a reaction, discontinue TRELSTAR and initiate appropriate medical management. ( 5.1 ) Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. This may worsen prostate cancer and result in spinal cord compression and urinary tract...
Contraindications. 4 CONTRAINDICATIONS Known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH. ( 4 ) 4.1 Hypersensitivity TRELSTAR is contraindicated in individuals with a known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH [ see Warnings and Precautions (5.1) ].
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.